vs

Side-by-side financial comparison of CPS TECHNOLOGIES CORP (CPSH) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $8.2M, roughly 1.5× CPS TECHNOLOGIES CORP). CPS TECHNOLOGIES CORP runs the higher net margin — 0.2% vs -1398.3%, a 1398.5% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 38.3%). CPS TECHNOLOGIES CORP produced more free cash flow last quarter ($-487.0K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 17.8%).

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CPSH vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.5× larger
RNA
$12.5M
$8.2M
CPSH
Growing faster (revenue YoY)
RNA
RNA
+395.7% gap
RNA
434.0%
38.3%
CPSH
Higher net margin
CPSH
CPSH
1398.5% more per $
CPSH
0.2%
-1398.3%
RNA
More free cash flow
CPSH
CPSH
$156.4M more FCF
CPSH
$-487.0K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
17.8%
CPSH

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CPSH
CPSH
RNA
RNA
Revenue
$8.2M
$12.5M
Net Profit
$12.6K
$-174.4M
Gross Margin
14.9%
Operating Margin
-1.2%
-1513.5%
Net Margin
0.2%
-1398.3%
Revenue YoY
38.3%
434.0%
Net Profit YoY
101.3%
-117.0%
EPS (diluted)
$0.00
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPSH
CPSH
RNA
RNA
Q4 25
$8.2M
Q3 25
$8.8M
$12.5M
Q2 25
$8.1M
$3.8M
Q1 25
$7.5M
$1.6M
Q4 24
$5.9M
$3.0M
Q3 24
$4.2M
$2.3M
Q2 24
$5.0M
$2.0M
Q1 24
$5.9M
$3.5M
Net Profit
CPSH
CPSH
RNA
RNA
Q4 25
$12.6K
Q3 25
$208.0K
$-174.4M
Q2 25
$103.8K
$-157.3M
Q1 25
$96.0K
$-115.8M
Q4 24
$-995.2K
$-102.3M
Q3 24
$-1.0M
$-80.4M
Q2 24
$-954.3K
$-70.8M
Q1 24
$-143.2K
$-68.9M
Gross Margin
CPSH
CPSH
RNA
RNA
Q4 25
14.9%
Q3 25
17.1%
Q2 25
16.5%
Q1 25
16.4%
Q4 24
-4.6%
Q3 24
-12.3%
Q2 24
-4.6%
Q1 24
15.3%
Operating Margin
CPSH
CPSH
RNA
RNA
Q4 25
-1.2%
Q3 25
3.1%
-1513.5%
Q2 25
1.7%
-4448.7%
Q1 25
1.7%
-8360.9%
Q4 24
-22.2%
-4069.6%
Q3 24
-35.0%
-4200.9%
Q2 24
-26.1%
-4040.4%
Q1 24
-4.4%
-2178.6%
Net Margin
CPSH
CPSH
RNA
RNA
Q4 25
0.2%
Q3 25
2.4%
-1398.3%
Q2 25
1.3%
-4089.3%
Q1 25
1.3%
-7360.0%
Q4 24
-16.8%
-3439.5%
Q3 24
-24.6%
-3441.7%
Q2 24
-19.0%
-3461.8%
Q1 24
-2.4%
-1943.4%
EPS (diluted)
CPSH
CPSH
RNA
RNA
Q4 25
$0.00
Q3 25
$0.01
$-1.27
Q2 25
$0.01
$-1.21
Q1 25
$0.01
$-0.90
Q4 24
$-0.07
$-0.80
Q3 24
$-0.07
$-0.65
Q2 24
$-0.07
$-0.65
Q1 24
$-0.01
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPSH
CPSH
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$13.2M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$24.6M
$1.9B
Total Assets
$29.5M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPSH
CPSH
RNA
RNA
Q4 25
$13.2M
Q3 25
$4.3M
$350.2M
Q2 25
$3.4M
$243.9M
Q1 25
$3.0M
$254.2M
Q4 24
$4.3M
$219.9M
Q3 24
$5.7M
$370.2M
Q2 24
$7.1M
$575.8M
Q1 24
$8.7M
$471.4M
Total Debt
CPSH
CPSH
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.1K
Q3 24
$20.1K
Q2 24
$31.9K
Q1 24
$43.5K
Stockholders' Equity
CPSH
CPSH
RNA
RNA
Q4 25
$24.6M
Q3 25
$15.1M
$1.9B
Q2 25
$14.9M
$1.2B
Q1 25
$14.7M
$1.3B
Q4 24
$14.5M
$1.4B
Q3 24
$15.4M
$1.5B
Q2 24
$16.4M
$1.2B
Q1 24
$17.3M
$830.9M
Total Assets
CPSH
CPSH
RNA
RNA
Q4 25
$29.5M
Q3 25
$20.4M
$2.1B
Q2 25
$19.4M
$1.4B
Q1 25
$19.2M
$1.5B
Q4 24
$18.9M
$1.6B
Q3 24
$19.2M
$1.6B
Q2 24
$20.1M
$1.3B
Q1 24
$21.2M
$951.5M
Debt / Equity
CPSH
CPSH
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPSH
CPSH
RNA
RNA
Operating Cash FlowLast quarter
$243.6K
$-156.2M
Free Cash FlowOCF − Capex
$-487.0K
$-156.9M
FCF MarginFCF / Revenue
-5.9%
-1257.6%
Capex IntensityCapex / Revenue
8.9%
5.7%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$-479.6K
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPSH
CPSH
RNA
RNA
Q4 25
$243.6K
Q3 25
$1.1M
$-156.2M
Q2 25
$649.3K
$-199.7M
Q1 25
$-1.3M
$-124.8M
Q4 24
$-3.5M
$-99.9M
Q3 24
$-1.2M
$-65.6M
Q2 24
$-1.0M
$-65.0M
Q1 24
$128.9K
$-70.4M
Free Cash Flow
CPSH
CPSH
RNA
RNA
Q4 25
$-487.0K
Q3 25
$876.8K
$-156.9M
Q2 25
$476.4K
$-203.0M
Q1 25
$-1.3M
$-128.6M
Q4 24
$-4.5M
$-103.8M
Q3 24
$-1.3M
$-67.3M
Q2 24
$-1.6M
$-65.5M
Q1 24
$-134.5K
$-71.3M
FCF Margin
CPSH
CPSH
RNA
RNA
Q4 25
-5.9%
Q3 25
10.0%
-1257.6%
Q2 25
5.9%
-5277.1%
Q1 25
-17.9%
-8174.3%
Q4 24
-75.3%
-3491.0%
Q3 24
-29.8%
-2881.8%
Q2 24
-31.8%
-3204.6%
Q1 24
-2.3%
-2012.3%
Capex Intensity
CPSH
CPSH
RNA
RNA
Q4 25
8.9%
Q3 25
2.0%
5.7%
Q2 25
2.1%
86.9%
Q1 25
1.2%
238.6%
Q4 24
16.8%
131.7%
Q3 24
1.9%
72.9%
Q2 24
11.0%
26.0%
Q1 24
4.5%
25.8%
Cash Conversion
CPSH
CPSH
RNA
RNA
Q4 25
19.34×
Q3 25
5.05×
Q2 25
6.25×
Q1 25
-13.05×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons